Revlimid

FDA warns about deaths in cancer drug trials
FDA warns about deaths in cancer drug trialsAn increased risk of deaths for patients in clinical trials receiving this cancer drug and two other drugs led FDA to stop the clinical trials.
FDA approves a new immune-stimulating drug to treat multiple myelomaFDA has approved elotuzumab (Empliciti, Bristol-Myers Squibb and AbbVie) for the treatment of multiple myeloma.
FDA approves first immunostimulatory antibody for multiple myelomaAn oncology expert at ASH will present extended follow-up and overall survival data from ELOQUENT-2, the study on which Empliciti is approved.
FDA expands approval of Revlimid to include newly diagnosed multiple myelomaFDA expanded approval of lenalidomide (Revlimid, Celgene) for the treatment of multiple myeloma. Revlimid acts as an immunomodulating agent and inhibits the growth of myeloma cells by inducing cell cycle arrest and cell death.
FDA drug approvals-February 2015FDA actions in brief, priority review, breakthrough designations, orphan drug designations
Lenalidomide now approved for treatment of MCLFDA has approved a new indication for lenalidomide (Revlimid, Celgene) for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.